SG81976A1 - Substituted tricyclics - Google Patents

Substituted tricyclics

Info

Publication number
SG81976A1
SG81976A1 SG9901681A SG1999001681A SG81976A1 SG 81976 A1 SG81976 A1 SG 81976A1 SG 9901681 A SG9901681 A SG 9901681A SG 1999001681 A SG1999001681 A SG 1999001681A SG 81976 A1 SG81976 A1 SG 81976A1
Authority
SG
Singapore
Prior art keywords
substituted tricyclics
tricyclics
substituted
Prior art date
Application number
SG9901681A
Other languages
English (en)
Inventor
Benjamin Alan Anderson
Nicholas James Bach
Jolie Anne Bastian
Nancy Kay Harn
Richard Waltz Harper
Gary Alan Hite
Michael Dean Kinnick
Ho-Shen Lin
Richard James Loncharich
John Mcneill Mcgill Iii
Edward David Mihelich
John Michael Junior Morin
Michael Leroy Phillips
Michael Enrico Richett
Daniel Jon Sall
Jason Scott Sawyer
Richard Walter Schevitz
Robert Theodore Vasileff
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG81976A1 publication Critical patent/SG81976A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG9901681A 1998-04-17 1999-04-16 Substituted tricyclics SG81976A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
SG81976A1 true SG81976A1 (en) 2001-07-24

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
SG9901869A SG81977A1 (en) 1998-04-17 1999-04-16 Substituted tricyclics
SG9901681A SG81976A1 (en) 1998-04-17 1999-04-16 Substituted tricyclics

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG9901869A SG81977A1 (en) 1998-04-17 1999-04-16 Substituted tricyclics

Country Status (30)

Country Link
EP (2) EP0952149B1 (ko)
JP (2) JP4435330B2 (ko)
KR (2) KR19990083232A (ko)
CN (1) CN1149193C (ko)
AR (2) AR018186A1 (ko)
AT (2) ATE268756T1 (ko)
AU (2) AU753436B2 (ko)
BR (2) BR9901279A (ko)
CA (2) CA2269262A1 (ko)
CO (2) CO5031247A1 (ko)
CZ (2) CZ136999A3 (ko)
DE (2) DE69918590T2 (ko)
DK (1) DK0950657T3 (ko)
DZ (1) DZ2769A1 (ko)
EA (2) EA002816B1 (ko)
ES (2) ES2226286T3 (ko)
HU (2) HUP9901220A3 (ko)
ID (2) ID23287A (ko)
IL (2) IL129485A0 (ko)
NO (2) NO312240B1 (ko)
NZ (3) NZ335253A (ko)
PE (2) PE20000476A1 (ko)
PL (2) PL332565A1 (ko)
PT (1) PT950657E (ko)
SG (2) SG81977A1 (ko)
SI (1) SI0950657T1 (ko)
TR (2) TR199900843A2 (ko)
TW (1) TWI238160B (ko)
YU (2) YU19199A (ko)
ZA (2) ZA992771B (ko)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513555A (ja) * 1997-08-28 2001-09-04 イーライ・リリー・アンド・カンパニー 非リウマチ様関節炎の処置方法
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
EP1214041A2 (en) * 1998-12-21 2002-06-19 Eli Lilly And Company Combination therapy for the treatment of sepsis
CA2379208A1 (en) * 1999-07-19 2001-01-25 Eli Lilly & Company Spla2 inhibitors
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
US20040102442A1 (en) * 2000-06-29 2004-05-27 Kohji Hanasaki Remedies for alzheimer's disease
US6967200B2 (en) 2000-06-29 2005-11-22 Shionogi & Co., Ltd. Remedies for cirrhosis
ES2294003T3 (es) * 2000-06-29 2008-04-01 Anthera Pharmaceuticals, Inc. Remedios contra el cancer.
BR0112460A (pt) * 2000-07-14 2003-07-22 Lilly Co Eli Método para tratamento de sépsis
EP1345898A2 (en) 2000-12-18 2003-09-24 Eli Lilly And Company Teracyclic carbazole derivates and their use as spla2 inhibitors
WO2002079154A1 (en) * 2001-03-28 2002-10-10 Eli Lilly And Company Substituted carbazoles as inhibitors of spla2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
BRPI0913986A2 (pt) 2008-03-26 2015-10-20 Daiichi Sankyo Co Ltd composto, composição farmacêutica, e, uso de um composto
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
EP2379538A4 (en) * 2009-01-22 2013-01-02 Orchid Res Lab Ltd HETEROCYCLIC COMPOUNDS AS A PHOSOPHODIESTERASE HEMMER
CA2757679A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2011097233A1 (en) 2010-02-03 2011-08-11 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
CN104837489A (zh) 2012-11-30 2015-08-12 通用电气健康护理有限公司 三环吲哚衍生物的结晶方法
IN2015DN03939A (ko) * 2012-11-30 2015-10-02 Ge Healthcare Ltd
WO2016116527A1 (de) * 2015-01-20 2016-07-28 Cynora Gmbh Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
EP0839806A1 (en) * 1996-10-30 1998-05-06 Eli Lilly And Company Substituted tricyclics
WO1999016453A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
WO1993001169A2 (en) * 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
DE69610793T2 (de) * 1995-06-23 2001-05-03 Eli Lilly And Co., Indianapolis 6-Subsitituierte-1,2,3,4-tetrahydro-9H-Carbazole und 7-substituierte-1OH-Cyclohepta(7,6-B)-Indole
CA2240395A1 (en) * 1995-12-13 1997-06-19 David Kent Herron Naphthyl acetamides as spla2 inhibitors
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
EP0839806A1 (en) * 1996-10-30 1998-05-06 Eli Lilly And Company Substituted tricyclics
WO1999016453A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease

Also Published As

Publication number Publication date
EA002816B1 (ru) 2002-10-31
ES2226286T3 (es) 2005-03-16
DE69918590T2 (de) 2005-07-21
DK0950657T3 (da) 2004-11-22
PT950657E (pt) 2004-11-30
SG81977A1 (en) 2001-07-24
HU9901221A (hu) 2000-04-28
AU2381999A (en) 1999-10-28
BR9902365A (pt) 2001-04-24
YU18999A (sh) 2002-08-12
EP0952149A2 (en) 1999-10-27
IL129483A0 (en) 2000-02-29
YU19199A (sh) 2002-08-12
SI0950657T1 (en) 2005-02-28
KR19990083232A (ko) 1999-11-25
PL332566A1 (en) 1999-10-25
DE69917833D1 (de) 2004-07-15
DE69918590D1 (de) 2004-08-19
TR199900853A3 (tr) 1999-11-22
KR100586761B1 (ko) 2006-06-08
CZ137099A3 (cs) 1999-11-17
NO991821L (no) 1999-10-18
TR199900843A2 (xx) 2000-02-21
NO991821D0 (no) 1999-04-16
NO312240B1 (no) 2002-04-15
EA002347B1 (ru) 2002-04-25
ZA992772B (en) 2002-07-16
HU9901220A (hu) 2000-04-28
CA2269246A1 (en) 1999-10-17
AR018186A1 (es) 2001-10-31
NZ335253A (en) 2000-11-24
EA199900301A2 (ru) 1999-10-28
NZ507564A (en) 2002-10-25
NO991822D0 (no) 1999-04-16
ID23287A (id) 2000-04-05
EP0950657A2 (en) 1999-10-20
ATE271037T1 (de) 2004-07-15
CN1253948A (zh) 2000-05-24
TWI238160B (en) 2005-08-21
NO314400B1 (no) 2003-03-17
ES2222663T3 (es) 2005-02-01
CO5011054A1 (es) 2001-02-28
PL332565A1 (en) 1999-10-25
ATE268756T1 (de) 2004-06-15
NO991822L (no) 1999-10-18
HUP9901220A3 (en) 2001-11-28
AR018593A1 (es) 2001-11-28
CO5031247A1 (es) 2001-04-27
ID23761A (id) 2000-05-11
EP0950657B1 (en) 2004-07-14
EP0952149A3 (en) 2001-08-16
KR19990083233A (ko) 1999-11-25
DE69917833T2 (de) 2005-07-14
EP0950657A3 (en) 2001-08-16
JPH11322713A (ja) 1999-11-24
BR9901279A (pt) 2000-05-02
CN1149193C (zh) 2004-05-12
ZA992771B (en) 2002-04-18
CA2269246C (en) 2009-08-25
CA2269262A1 (en) 1999-10-17
EP0952149B1 (en) 2004-06-09
EA199900303A2 (ru) 1999-10-28
HUP9901221A3 (en) 2001-11-28
JP4435330B2 (ja) 2010-03-17
PE20000432A1 (es) 2000-05-23
AU753547B2 (en) 2002-10-24
EA199900301A3 (ru) 2000-04-24
JP2000026416A (ja) 2000-01-25
DZ2769A1 (fr) 2003-12-01
AU753436B2 (en) 2002-10-17
HU9901220D0 (en) 1999-06-28
EA199900303A3 (ru) 2000-04-24
PE20000476A1 (es) 2000-06-02
HU9901221D0 (en) 1999-06-28
NZ335251A (en) 2000-11-24
TR199900853A2 (xx) 1999-11-22
AU2381799A (en) 1999-10-28
IL129485A0 (en) 2000-02-29
CZ136999A3 (cs) 1999-11-17

Similar Documents

Publication Publication Date Title
IL129485A0 (en) Substituted tricyclics
DE59912932D1 (en) Arylphenylsubstituierte cyclische ketoenole
DE59912303D1 (en) Arylphenylsubstituierte cyclische ketoenole
GB2342193B (en) Addition circuitry
PL341642A1 (en) Novel macrolydes
DE69904335D1 (en) Aminomethylcarbonsäurederivate
DE69835235D1 (en) Thermoplastische silikonelastomere
DE59903023D1 (en) Perorale wirkstoff-suspension
IL129481A0 (en) Substituted tricyclics
DE59914151D1 (en) Arylalkanoylpyridazine
IL129484A0 (en) Substituted tricyclics
EP1068213A4 (en) SILOXANES WITH AMINO-ORGANIC FUNCTIONAL GROUP
DE60042897D1 (en) Photovervielfacherröhre
DE59904407D1 (en) Chromanderivate
GB9816729D0 (en) Substituted cyclohexylaminopyrimidines
HK1039937A1 (zh) 取代的3-硫代氨基甲酰基吡唑類化合物
DE69821502D1 (en) Boroskop
PL347397A1 (en) Substituted 3-aryl-pyrazoles
DE59900495D1 (en) Multimetalloxidmassen
DE59900471D1 (en) Inchbremseinrichtung
PL345866A1 (en) Substituted cyclooctadepsipeptides
HK1039335A1 (zh) 取代的苯甲酰基環已二酮類化合物
DE69902586D1 (en) Expandierte ethylencopolymere
DE59905941D1 (en) Methoximinophenylessigsäureamide
DE59911094D1 (en) Tryptase-inhibitoren